中度扩张升主动脉手术与监测的患者选择:TITAN:SvS国际前瞻性试验启示
TITAN:SvS是一项前瞻性多中心国际试验,纳入升主动脉直径5.0-5.4 cm的胸主动脉瘤患者,随机分为初始手术组与监测组,非随机患者进入登记组。比较随机组与登记组特征发现,监测登记组患者更年长且合并症更多,而主动脉最大直径无显著差异;加拿大患者更倾向于被随机分组。结论提示患者特征和地域因素而非主动脉大小影响初始治疗决策。
要点
- 监测登记组患者比随机组和手术登记组更年长、合并症更多。
核心结论
- 患者特征和地域因素而非主动脉大小影响升主动脉瘤初始治疗策略的选择。
- 手术登记组可能排除病情更重的患者,推广其结果时需谨慎。
研究设计与样本
- TITAN:SvS为前瞻性、多中心、国际试验,纳入升主动脉直径5.0-5.4 cm的患者,随机1:1分为初始手术组与监测组,非随机患者进入登记组前瞻性监测。
- 2018至2023年在美国和加拿大22个中心共纳入615例患者。
主要发现
- 监测登记组患者比随机组和手术登记组更年长且合并症更多。
临床怎么用
- 临床决策应综合考虑患者年龄、合并症和地域实践模式,而非仅依据主动脉直径。
- 引用手术登记研究结果时需警惕选择偏倚,因其可能排除病情更重的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Guidelines for treating ascending thoracic aortic aneurysms (ATAA) are largely based on single-center studies. To understand factors influencing patient selection for surgery vs surveillance, patient and aneurysm characteristics were compared for patients in the randomized and registry arms of a large prospective, multicenter, multinational trial. METHODS: TITAN:SvS (Treatment in Thoracic Aortic aNeurysm: Surgery versus Surveillance) is a large prospective multicenter study of patients with ATAA between 5.0 and 5.4 cm, randomizing patients 1:1 to initial surgery vs surveillance. Nonrandomized patients are enrolled into a registry where results of operative or surveillance strategy can be monitored prospectively. Between 2018 and 2023, 615 patients were enrolled at 22 sites in the United States and Canada. Demographic and aneurysm characteristics were compared between randomized and registry arms. RESULTS: Compared with randomized and operative registry groups, patients in the surveillance registry were older with more comorbidities. No significant differences were observed in maximal ascending aortic diameter (5.1 cm [interquartile range, 5.0-5.2 cm] vs 5.1 cm [interquartile range, 4.9-5.2 cm] P = .2) or other aneurysm characteristics. Despite similar numbers of enrolling centers in the United States (n = 11) and Canada (n = 12), Canadian patients were more likely to be randomized (58% vs 7%, P < .01) and less likely to be enrolled in the operative (9% vs 42%, P < .01) or surveillance registry (34% vs 51%). CONCLUSIONS: Enrollment data for TITAN:SvS suggest that patient and geographic characteristics, rather than aortic size, influence decision-making regarding the initial treatment strategy for ATAAs. These findings highlight the need for caution when generalizing outcomes from operative registries, because sicker patients may be excluded.
引用
- Makarem A, Appoo JJ, Boodhwani M, et al. Patient Selection for Surgery vs Surveillance in Moderately Dilated Ascending Aorta: Insights From Treatment in Thoracic Aortic Aneurysm: Surgery versus Surveillance (TITAN:SvS), an International Prospective Trial. Ann Thorac Surg. 2025. PMID: 39923952. doi:10.1016/j.athoracsur.2025.01.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。